Reports of the successful trials that could lead to the world's first malaria vaccine led the headlines of international news outlets this week. Hidden within the story line is the critical role of researchers at the
"Congratulations are due to the many former and current WRAIR investigators who have helped to develop and test this vaccine over the last 20 years," said Col.
Results on the RTS,S phase III vaccine trial being conducted in
The phase III study involved more than 15,000 children across 11 sites in seven African countries. The results demonstrated a 46% reduction in clinical malaria episodes among infants and children vaccinated at five to 17 months of age and 27% among infants vaccinated at six to 12 weeks.
According to the
Malaria is a mosquito-borne parasitic disease that kills hundreds of thousands of people each year. Although initial results indicate positive outcomes over the short term, results over the long term suggest the effectiveness of the vaccine decreases over time. Ongoing research will explore whether a booster dose can increase protection over the long term (after 18 months) as well as other tools, such as the use of bed nets, to reduce risk.
The successful trials give hope that a malaria vaccine will be available by 2015, the same year in which
For additional information, please visit:
USAMRU Kenya: http://www.usamrukenya.org/
USAMRU-K DEID: http://usamrukenya-deid.org/
Malaria Vaccine Initiative (MVI) Path: http://www.malariavaccine.org/about-overview.php
Army Medicine: http://armymedicine.mil/Pages/Home.aspx
TNS 30FurigayJane-131012-4516659 30FurigayJane
Most Popular Stories
- Obamacare Doing Just Fine, Ky. Governor Says
- Twitter Names Woman to Board
- Rand Paul Signs up for Obamacare
- Aspen Contracting Adding 300 Jobs
- Hispanic Employment Improves in November
- U.S. Chamber to Run Ads in Idaho, W.Va.
- Trapped Florida Whales Head for Deeper Waters
- U.S. Unemployment Rate Dips to 7 Percent
- Consumer Spending Rises, Incomes Fall
- American Eagle Issues Weak Q4 Outlook